ACC.26 advanced registration ends Feb. 12 – register now!

Daniel B. Mark, MD, MPH, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis Corporation(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Elsevier(SIGNIFICANT)

View Full Disclosure